← Back to Search

Anti-metabolites

pemetrexed for Lymphoma

Phase 2
Waitlist Available
Research Sponsored by Northwestern University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up after 6 months of treatment
Awards & highlights

Study Summary

This trial is studying pemetrexed disodium to see how well it works in treating patients with recurrent malignant gliomas, primary CNS lymphoma, or brain metastases.

Eligible Conditions
  • Lymphoma
  • Brain Tumor
  • Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~after 6 months of treatment
This trial's timeline: 3 weeks for screening, Varies for treatment, and after 6 months of treatment for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Progression free survival at 6 months and time to disease progression
Secondary outcome measures
Collect safety data
Compare blood and tissue methylation patterns and correlate with response.
Overall survival
+1 more

Side effects data

From 2022 Phase 3 trial • 1274 Patients • NCT02220894
12%
Weight decreased
9%
Diarrhoea
9%
Arthralgia
9%
Constipation
9%
Haemoptysis
9%
Hypothyroidism
9%
Aspartate aminotransferase increased
9%
Decreased appetite
9%
Alanine aminotransferase increased
9%
Nasopharyngitis
9%
Bronchitis
6%
Cough
6%
Asthenia
6%
Anaemia
6%
Pruritus
6%
Pneumonia
6%
Headache
6%
Blood alkaline phosphatase increased
3%
Hyperthyroidism
3%
Lymph gland infection
3%
Pneumonia bacterial
3%
Myalgia
3%
White blood cell count decreased
3%
Tumour associated fever
3%
Subdural haemorrhage
3%
Nausea
3%
Rash
3%
Leukopenia
3%
Malaise
3%
Upper respiratory tract infection
3%
Hypertension
3%
Pyrexia
3%
Dyspnoea
3%
Back pain
3%
Chest pain
3%
Haematemesis
3%
Hyperglycaemia
3%
Upper gastrointestinal haemorrhage
3%
Oedema peripheral
100%
80%
60%
40%
20%
0%
Study treatment Arm
Pembrolizumab Second Course
Pembrolizumab
Chemotherapy (SOC Treatment)

Trial Design

1Treatment groups
Experimental Treatment
Group I: Treatment ArmExperimental Treatment1 Intervention
Pemetrexed 900 mg/m2 every 21 days until disease progression.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Pemetrexed
FDA approved

Find a Location

Who is running the clinical trial?

National Cancer Institute (NCI)NIH
13,703 Previous Clinical Trials
40,931,719 Total Patients Enrolled
1,391 Trials studying Lymphoma
382,423 Patients Enrolled for Lymphoma
Northwestern UniversityLead Sponsor
1,600 Previous Clinical Trials
920,168 Total Patients Enrolled
50 Trials studying Lymphoma
1,130 Patients Enrolled for Lymphoma
Jeffrey J. Raizer, MDStudy ChairRobert H. Lurie Cancer Center
8 Previous Clinical Trials
210 Total Patients Enrolled
2 Trials studying Lymphoma
15 Patients Enrolled for Lymphoma

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Pemetrexed Disodium in Treating Patients With Recurrent Malignant Gliomas, Primary CNS Lymphoma, or Brain Metastases
2005. "Pemetrexed Disodium in Treating Patients With Recurrent Malignant Gliomas, Primary CNS Lymphoma, or Brain Metastases". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT00276783.
All > Bone Metastases
~2 spots leftby May 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top